Danica Pension Livsforsikringsaktieselskab Buys Shares of 10,212 Stryker Corporation $SYK

Danica Pension Livsforsikringsaktieselskab acquired a new stake in Stryker Corporation (NYSE:SYK) during the 1st quarter, Holdings Channel reports. The institutional investor acquired 10,212 shares of the medical technology company’s stock, valued at approximately $3,356,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of SYK. VanderPol Investments L.L.C. lifted its holdings in Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after buying an additional 28 shares in the last quarter. KCM Investment Advisors LLC grew its position in shares of Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after buying an additional 28 shares in the last quarter. Rossby Financial LCC grew its position in shares of Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after buying an additional 28 shares in the last quarter. Tcfg Wealth Management LLC increased its stake in shares of Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after buying an additional 29 shares during the period. Finally, Mechanics Financial Corp raised its holdings in shares of Stryker by 1.2% in the fourth quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock valued at $864,000 after acquiring an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 over the last three months. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research reports. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research note on Friday, May 1st. Robert W. Baird set a $385.00 price target on shares of Stryker in a report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research report on Friday, May 1st. Leerink Partners cut their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Finally, Truist Financial reissued a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average price target of $392.52.

Stryker Stock Performance

Shares of Stryker stock opened at $309.50 on Thursday. The company has a market capitalization of $118.65 billion, a PE ratio of 35.82, a P/E/G ratio of 2.02 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a 50-day simple moving average of $313.94 and a two-hundred day simple moving average of $335.90. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the prior year, the business posted $2.84 earnings per share. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts expect that Stryker Corporation will post 14.99 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is presently 40.74%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.